Effect of Omalizumab as Add-On Therapy on Asthma-Related Quality of Life in Severe Allergic Asthma: A Brazilian Study (QUALITX)
Journal of Asthma, 03/21/2012Rubin AS et al.
Omalizumab was well tolerated and significantly improved the overall Asthma–related Quality of Life Questionnaire score. Hence, it is a potential add–on therapy for severe persistent allergic asthma not controlled by standard prescribed treatment in Brazilian patients.
This was a 20–week, randomized, open–label, study involving Brazilian patients (>12 years) with severe persistent allergic asthma inadequately controlled despite regular treatment with, at least, ICS (≥500 μg/day fluticasone or equivalent) ++ LABA.
The primary objective was to assess the mean change from baseline in overall Asthma–related Quality of Life Questionnaire (AQLQ) score in omalizumab–treated patients compared with the control group.
Secondary outcome measures included rescue medication use, incidence of asthma exacerbations, perception of treatment efficacy among patients, mean change from baseline in AQLQ score, and >1.5–point increase in overall AQLQ score.
In the omalizumab group, overall AQLQ score was 3.2 (0.9) (mean [SD]) at baseline and 4.4 (1.3) at week 20 versus 3.0 (1.0) at baseline and 3.0 (1.1) at week 20 in the control group.
Mean change from baseline on overall AQLQ score at week 20 in the omalizumab group was 1.2 (0.2) versus 0 (0.1) in the control group, showing a significant increase in scores from baseline in the omalizumab group (p < .001).
There was also a statistically significant difference (p < .001) in the number of patients who showed a >1.5–point increase from baseline in overall AQLQ score after 20 weeks, thus indicating a better QoL in the omalizumab group.
There was no significant difference with respect to the use of rescue medication, incidence of asthma exacerbation, and adverse events between treatment groups.
The global evaluation of treatment effectiveness was significantly better for omalizumab (p < .001).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.